Geneva, April 2023. The partnership between Concept Foundation and MirZyme is a critical step toward in the prevention and treatment of pre-eclampsia. This life-threatening disease is a major public health issue that affects expectant mothers and infants around the world. There are currently no accurate diagnostics or approved therapeutics available for treating pre-eclampsia. Pre-eclampsia affects maternal and infant health in pregnancy and survivors are likely to suffer from cardiovascular disease later in life.
This partnership between a global not-for-profit organisation and an innovative female health biotech aims to make pre-eclampsia history by developing effective novel therapies and ensuring global access to these treatments. Together, these two organisations bring together expertise and resources to accelerate the development of new therapies and implement innovative products in both high income countries and essentially, in low- and middle-income countries where the need is most critical.
The dedication and talent of the individuals involved in this partnership are essential to achieving this important goal. Together, they will work towards reducing the burden of pre-eclampsia and improving the health outcomes for mothers and babies worldwide.
In addition to orally active therapeutics, MirZyme has developed a definitive diagnostic tool to diagnose women who will go on to develop pre-eclampsia. This has completed a prospective clinical study of over 500 patients and has shown over 95% accuracy in detecting early pre-eclampsia.
Dr A. Metin Gülmezoglu Executive Director of Concept Foundation said,
As an organization, we are committed to ensuring affordable access to new safe and effective health technologies in low and middle-income countries. This collaboration forms an important part of our work to accelerate innovations for mothers and contributing to reducing inequities that affect the health and well-being of women. We are delighted to be partnering MirZyme Therapeutics who have developed both diagnostic and therapeutic innovations that are exciting and potentially game changing.
Professor Asif Ahmed Founder and Executive Chairman of MirZyme Therapeutics said, “I am delighted to have Concept Foundation working with MirZyme with a common mission to make pre-eclampsia history. It is a fantastic opportunity to work with talented and dedicated individuals at the Concept Foundation who bring a vast amount of experience and global network to support our mission”.
Media and Communication Contact
Note for Editors:
Concept Foundation (www.conceptfoundation.org) is an international non-governmental; and not-for-profit organisation working to ensure that quality-assured, safe and effective maternal and reproductive health products are widely accessible, in particular to the public sector of low- and middle-income countries at an affordable price.
MirZyme Therapeutics (www.mirzyme.com) is the end-to-end pre-eclampsia solution. It is an early-stage clinical female health biopharmaceutical company a laser-focus on developing solutions to predict and potentially prevent pre-eclampsia, a life-threatening hypertensive disorder of pregnancy. The UK medicines regulator, the MHRA awarded MirZyme a fast-track award, the Innovation Passport. Innovation Passport is a prestigious UK scheme with global implications and benefits. MirZyme is the first company in women’s health to be awarded an innovation passport for one of its orally active new medicines.